Cytoskeleton markers (e.g., GFAP) were decreased in the ALS and A1 data sets but increased in the MCAO and SCI models, suggesting that they may play a role in neuroprotection. This evidence concerns the gene GFAP and amyotrophic lateral sclerosis.